Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer.
Glowing Tumor Technology Helps Surgeons Remove Hidden Cancer Cells
Penn Medicine Neurosurgeon Named Alpha Omega Alpha Fellow in Leadership
Cardiology Researcher Wins AHA Outstanding Early Career Investigator Award
Penn Center for Precision Medicine Awards $565,000 in Second Accelerator Grants
The Part of Obamacare Even Republicans Like
Football and Brain Injuries
$100 Sweetens the Pot for a Colonoscopy
One Big Cancer Breakthrough Is Likely on the Way to Patients – Here’s What May Be Coming Next
Philanthropy’s Part in a Major Advance in Cancer Treatment
UC San Diego Takes on Cancer Therapy Pioneered at Penn Medicine